Oncolytics Biotech Inc
TSX:ONC

Watchlist Manager
Oncolytics Biotech Inc Logo
Oncolytics Biotech Inc
TSX:ONC
Watchlist
Price: 14.9 CAD -1.32% Market Closed
Market Cap: 173.1m CAD

Oncolytics Biotech Inc
Cash from Financing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Oncolytics Biotech Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Oncolytics Biotech Inc
TSX:ONC
Cash from Financing Activities
CA$14.4m
CAGR 3-Years
42%
CAGR 5-Years
-18%
CAGR 10-Years
-7%
Theratechnologies Inc
TSX:TH
Cash from Financing Activities
-$22.8m
CAGR 3-Years
-36%
CAGR 5-Years
-27%
CAGR 10-Years
-46%
Repare Therapeutics Inc
NASDAQ:RPTX
Cash from Financing Activities
$110k
CAGR 3-Years
-90%
CAGR 5-Years
-79%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Cash from Financing Activities
-$127.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Cash from Financing Activities
$15.7m
CAGR 3-Years
-70%
CAGR 5-Years
-33%
CAGR 10-Years
-10%
Spectral Medical Inc
TSX:EDT
Cash from Financing Activities
CA$9.4m
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
5%
No Stocks Found

Oncolytics Biotech Inc
Glance View

Market Cap
173.1m CAD
Industry
Biotechnology

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.

ONC Intrinsic Value
Not Available

See Also

What is Oncolytics Biotech Inc's Cash from Financing Activities?
Cash from Financing Activities
14.4m CAD

Based on the financial report for Jun 30, 2025, Oncolytics Biotech Inc's Cash from Financing Activities amounts to 14.4m CAD.

What is Oncolytics Biotech Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-7%

Over the last year, the Cash from Financing Activities growth was -46%. The average annual Cash from Financing Activities growth rates for Oncolytics Biotech Inc have been 42% over the past three years , -18% over the past five years , and -7% over the past ten years .

Back to Top